相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry
Piotr Lewczuk et al.
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY (2018)
Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging
Suzanne E. Schindler et al.
ALZHEIMERS & DEMENTIA (2018)
Addition of the Aβ42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer's disease dementia in mild cognitive impairment
Ines Baldeiras et al.
ALZHEIMERS RESEARCH & THERAPY (2018)
Relevance of A beta 42/40 Ratio for Detection of Alzheimer Disease Pathology in Clinical Routine: The PLMR Scale
Sylvain Lehmann et al.
FRONTIERS IN AGING NEUROSCIENCE (2018)
Cerebrospinal Fluid A beta(42/40) Corresponds Better than A beta(42) to Amyloid PET in Alzheimer's Disease
Piotr Lewczuk et al.
JOURNAL OF ALZHEIMERS DISEASE (2017)
Cerebrospinal Fluid Aβ42/Aβ40 as a Means to Limiting Tube- and Storage-Dependent Pre-Analytical Variability in Clinical Setting
Christelle Gervaise-Henry et al.
JOURNAL OF ALZHEIMERS DISEASE (2017)
Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia
Lutz Frolich et al.
ALZHEIMERS RESEARCH & THERAPY (2017)
Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment
Shorena Janelidze et al.
JAMA NEUROLOGY (2017)
How to handle adsorption of cerebrospinal fluid amyloid β (1-42) in laboratory practice? Identifying problematic handlings and resolving the issue by use of the Aβ42/Aβ40 ratio
Eline Willemse et al.
ALZHEIMERS & DEMENTIA (2017)
Do we still need positron emission tomography for early Alzheimer's disease diagnosis?
Piotr Lewczuk et al.
BRAIN (2016)
Pittsburgh compound B imaging and cerebrospinal fluid amyloid-β in a multicentre European memory clinic study
Antoine Leuzy et al.
BRAIN (2016)
Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography
Sebastian Palmqvist et al.
BRAIN (2016)
Optimized Standard Operating Procedures for the Analysis of Cerebrospinal Fluid Aβ42 and the Ratios of Aβ Isoforms Using Low Protein Binding Tubes
Hugo Marcel Johan Vanderstichele et al.
JOURNAL OF ALZHEIMERS DISEASE (2016)
Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies
Olivier Bousiges et al.
JOURNAL OF ALZHEIMERS DISEASE (2016)
CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease
Shorena Janelidze et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2016)
Cerebral white matter lesions - associations with Aβ isoforms and amyloid PET
Danielle van Westen et al.
SCIENTIFIC REPORTS (2016)
Pre-analytical and analytical factors influencing Alzheimer's disease cerebrospinal fluid biomarker variability
Anthony Fourier et al.
CLINICA CHIMICA ACTA (2015)
Importance and Impact of Preanalytical Variables on Alzheimer Disease Biomarker Concentrations in Cerebrospinal Fluid
Nathalie Le Bastard et al.
CLINICAL CHEMISTRY (2015)
Cerebrospinal fluid Aβ40 is similarly reduced in patients with Frontotemporal Lobar Degeneration and Alzheimer's Disease
Ines Baldeiras et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2015)
Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study
Julien Dumurgier et al.
ALZHEIMERS RESEARCH & THERAPY (2015)
Chasing the effects of pre-analytical confounders - a multicenter study on CSF-AD biomarkers
Maria Joao Leitao et al.
FRONTIERS IN NEUROLOGY (2015)
Cerebrospinal Fluid Aβ40 Improves the Interpretation of Aβ42 Concentration for Diagnosing Alzheimer’s Disease
Aline Dorey et al.
Frontiers in Neurology (2015)
Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease
Niklas Mattsson et al.
BRAIN (2015)
Amyloid-β 42/40 Cerebrospinal Fluid Concentration Ratio in the Diagnostics of Alzheimer's Disease: Validation of Two Novel Assays
Piotr Lewczuk et al.
JOURNAL OF ALZHEIMERS DISEASE (2015)
Validation of the Erlangen Score Algorithm for the Prediction of the Development of Dementia due to Alzheimer's Disease in Pre-Dementia Subjects
Piotr Lewczuk et al.
JOURNAL OF ALZHEIMERS DISEASE (2015)
Diagnostic Accuracy of Cerebrospinal Fluid Amyloid-β Isoforms for Early and Differential Dementia Diagnosis
Hanne Struyfs et al.
JOURNAL OF ALZHEIMERS DISEASE (2015)
Additional Use of Aβ42/Aβ40 Ratio with Cerebrospinal Fluid Biomarkers P-Tau and Aβ42 Increases the Level of Evidence of Alzheimer's Disease Pathophysiological Process in Routine Practice
Mathilde Sauvee et al.
JOURNAL OF ALZHEIMERS DISEASE (2014)
Spreading of Amyloid, Tau, and Microvascular Pathology in Alzheimer's Disease: Findings from Neuropathological and Neuroimaging Studies
Dietmar Rudolf Thal et al.
JOURNAL OF ALZHEIMERS DISEASE (2014)
CSF biomarker variability in the Alzheimer's Association quality control program
Niklas Mattsson et al.
ALZHEIMERS & DEMENTIA (2013)
Evaluation of the Cerebrospinal Fluid Amyloid-β1-42/Amyloid-β1-40 Ratio Measured by Alpha-LISA to Distinguish Alzheimer's Disease from Other Dementia Disorders
Magdalena Nutu et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2013)
Cerebrospinal Fluid Aβ1-40 Improves Differential Dementia Diagnosis in Patients with Intermediate P-tau181P Levels
Sylvie Slaets et al.
JOURNAL OF ALZHEIMERS DISEASE (2013)
Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update
Marta del Campo et al.
BIOMARKERS IN MEDICINE (2012)
Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease
Anne M. Fagan et al.
BIOMARKERS IN MEDICINE (2012)
Risk of Alzheimer's Disease Biological Misdiagnosis Linked to Cerebrospinal Collection Tubes
Armand Perret-Liaudet et al.
JOURNAL OF ALZHEIMERS DISEASE (2012)
Performance of Aβ1-40, Aβ1-42, Total Tau, and Phosphorylated Tau as Predictors of Dementia in a Cohort of Patients with Mild Cognitive Impairment
Lucilla Parnetti et al.
JOURNAL OF ALZHEIMERS DISEASE (2012)
CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings
T. T. Seppala et al.
NEUROLOGY (2012)
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Reisa A. Sperling et al.
ALZHEIMERS & DEMENTIA (2011)
The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Guy M. McKhann et al.
ALZHEIMERS & DEMENTIA (2011)
The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Marilyn S. Albert et al.
ALZHEIMERS & DEMENTIA (2011)
Association Between In Vivo Fluorine 18-Labeled Flutemetamol Amyloid Positron Emission Tomography Imaging and In Vivo Cerebral Cortical Histopathology
David A. Wolk et al.
ARCHIVES OF NEUROLOGY (2011)
Neurochemical dementia diagnostics in Alzheimer's disease: where are we now and where are we going?
Piotr Lewczuk et al.
EXPERT REVIEW OF PROTEOMICS (2011)
Decreased sA beta PP beta, A beta(38), and A beta(40) Cerebrospinal Fluid Levels in Frontotemporal Dementia
Audrey Gabelle et al.
JOURNAL OF ALZHEIMERS DISEASE (2011)
The Cerebrospinal Fluid Amyloid β42/40 Ratio in the Differentiation of Alzheimer's Disease from Non-Alzheimer's Dementia
P. E. Spies et al.
CURRENT ALZHEIMER RESEARCH (2010)
Evaluation of CSF Biomarkers as Predictors of Alzheimer's Disease: A Clinical Follow-Up Study of 4.7 Years
Joakim Hertze et al.
JOURNAL OF ALZHEIMERS DISEASE (2010)
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
Kaj Blennow et al.
NATURE REVIEWS NEUROLOGY (2010)
Effects of cerebrovascular disease on amyloid precursor protein metabolites in cerebrospinal fluid
Per Selnes et al.
FLUIDS AND BARRIERS OF THE CNS (2010)
CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment
Niklas Mattsson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Neurochemical dementia diagnostics: a simple algorithm for interpretation of the CSF biomarkers
Piotr Lewczuk et al.
JOURNAL OF NEURAL TRANSMISSION (2009)
A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease
N. A. Verwey et al.
ANNALS OF CLINICAL BIOCHEMISTRY (2009)
Core candidate neurochemical and imaging biomarkers of Alzheimer's disease
Harald Hampel et al.
ALZHEIMERS & DEMENTIA (2008)
Amyloid β peptide ratio 42/40 but not Aβ42 correlates with phospho-Tau in patients with low- and high-CSF Aβ40 load
Jens Wiltfang et al.
JOURNAL OF NEUROCHEMISTRY (2007)
Prediction of Alzheimer's disease using the CSF A beta 42/A beta 40 ratio in patients with mild cognitive impairment
Oskar Hansson et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2007)
CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease
Katharina Buerger et al.
BRAIN (2006)
Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study
O Hansson et al.
LANCET NEUROLOGY (2006)
Effect of sample collection tubes on cerebrospinal fluid concentrations of tau proteins and amyloid β peptides
P Lewczuk et al.
CLINICAL CHEMISTRY (2006)
Safety and acceptability of the research lumbar puncture
ER Peskind et al.
ALZHEIMER DISEASE & ASSOCIATED DISORDERS (2005)
Neurochemical diagnosis of Alzheimer's dementia by CSF Aβ42, Aβ42/Aβ40 ratio and total tau
P Lewczuk et al.
NEUROBIOLOGY OF AGING (2004)
Mild cognitive impairment as a diagnostic entity
RC Petersen
JOURNAL OF INTERNAL MEDICINE (2004)
分享论文
